With Pfizer’s stock down sharply, an activist investor is pushing for something new from the CEO who spurred the company to ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Guggenheim has earned $172 million from advising Pfizer on nearly $400 billion in acquisitions since 2011. Pfizer’s stock has ...